866-997-4948(US-Canada Toll Free)

Alopecia - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 156 Pages

Alopecia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia Pipeline Review, H1 2017, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 4, 1, 18 and 8 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Alopecia - Overview 7
Alopecia - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Alopecia - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Alopecia - Companies Involved in Therapeutics Development 27
Aclaris Therapeutics Inc 27
Allergan Plc 27
Almirall SA 28
AndroScience Corp 28
Berg LLC 29
BiologicsMD Inc 29
BirchBioMed Inc 30
Bristol-Myers Squibb Company 30
Cassiopea SpA 31
Concert Pharmaceuticals Inc 31
Dong-A Socio Holdings Co Ltd 32
Follicum AB 32
Handok Inc 33
Histogen Inc 33
Hyundai Pharmaceutical Co Ltd 34
Incyte Corp 34
Kuhnil Pharmaceutical Co Ltd 35
Lee's Pharmaceutical Holdings Ltd 35
LEO Pharma A/S 36
Medivir AB 36
NovaLead Pharma Pvt Ltd 37
Novartis AG 37
Panacea Biotec Ltd 38
Pfizer Inc 38
Quark Pharmaceuticals Inc 39
RiverTown Therapeutics Inc 39
RXi Pharmaceuticals Corp 40
Samumed LLC 40
SWITCH Biotech LLC 41
Taisho Pharmaceutical Holdings Co Ltd 41
Tigo GmbH 42
viDA Therapeutics Inc 42
Alopecia - Drug Profiles 43
(cyclosporine A + minoxidil + RT-175) - Drug Profile 43
abatacept - Drug Profile 44
AI-001 - Drug Profile 51
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52
Antisense Oligonucleotide to Inhibit Androgen Receptor for Alopecia - Drug Profile 53
ASCJ-9 - Drug Profile 54
ATI-50001 - Drug Profile 56
ATI-50002 - Drug Profile 57
ATI-50003 - Drug Profile 58
bimatoprost - Drug Profile 59
BMD-1141 - Drug Profile 61
BMD-1341 - Drug Profile 62
BMD-2341 - Drug Profile 63
BQ-A - Drug Profile 64
BRM-421 - Drug Profile 65
calcitriol - Drug Profile 66
CB-0301 - Drug Profile 67
CTP-543 - Drug Profile 70
DHL-HisZnNa - Drug Profile 72
finasteride - Drug Profile 73
finasteride - Drug Profile 74
FOL-005 - Drug Profile 75
HGEN-001 - Drug Profile 78
HL-5945 - Drug Profile 80
HTB-005 - Drug Profile 81
interferon beta-1b - Drug Profile 82
KI-1104 - Drug Profile 83
KI-1105 - Drug Profile 84
LEO-124249 - Drug Profile 85
minoxidil - Drug Profile 86
NLP-602 - Drug Profile 87
OLX-104 - Drug Profile 88
PF-06651600 - Drug Profile 89
PF-06700841 - Drug Profile 90
QPAL-1 - Drug Profile 92
QPAL-2 - Drug Profile 93
Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 94
remetinostat - Drug Profile 95
ruxolitinib phosphate - Drug Profile 98
Samcyprone - Drug Profile 113
secukinumab - Drug Profile 115
setipiprant - Drug Profile 128
SM-04554 - Drug Profile 130
Small Molecule for Androgenic Alopecia - Drug Profile 132
Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 133
Synthetic Peptide for Alopecia - Drug Profile 134
TASP-0382088 - Drug Profile 135
TS-133 - Drug Profile 136
VTI-1000 Series - Drug Profile 137
ZK-003 - Drug Profile 138
Alopecia - Dormant Projects 139
Alopecia - Discontinued Products 141
Alopecia - Product Development Milestones 142
Featured News & Press Releases 142
Appendix 151
Methodology 151
Coverage 151
Secondary Research 151
Primary Research 151
Expert Panel Validation 151
Contact Us 151
Disclaimer 152

List of Tables
Number of Products under Development for Alopecia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Alopecia - Pipeline by Aclaris Therapeutics Inc, H1 2017
Alopecia - Pipeline by Allergan Plc, H1 2017
Alopecia - Pipeline by Almirall SA, H1 2017
Alopecia - Pipeline by AndroScience Corp, H1 2017
Alopecia - Pipeline by Berg LLC, H1 2017
Alopecia - Pipeline by BiologicsMD Inc, H1 2017
Alopecia - Pipeline by BirchBioMed Inc, H1 2017
Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2017
Alopecia - Pipeline by Cassiopea SpA, H1 2017
Alopecia - Pipeline by Concert Pharmaceuticals Inc, H1 2017
Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Alopecia - Pipeline by Follicum AB, H1 2017
Alopecia - Pipeline by Handok Inc, H1 2017
Alopecia - Pipeline by Histogen Inc, H1 2017
Alopecia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
Alopecia - Pipeline by Incyte Corp, H1 2017
Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Alopecia - Pipeline by LEO Pharma A/S, H1 2017
Alopecia - Pipeline by Medivir AB, H1 2017
Alopecia - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
Alopecia - Pipeline by Novartis AG, H1 2017
Alopecia - Pipeline by Panacea Biotec Ltd, H1 2017
Alopecia - Pipeline by Pfizer Inc, H1 2017
Alopecia - Pipeline by Quark Pharmaceuticals Inc, H1 2017
Alopecia - Pipeline by RiverTown Therapeutics Inc, H1 2017
Alopecia - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Alopecia - Pipeline by Samumed LLC, H1 2017
Alopecia - Pipeline by SWITCH Biotech LLC, H1 2017
Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
Alopecia - Pipeline by Tigo GmbH, H1 2017
Alopecia - Pipeline by viDA Therapeutics Inc, H1 2017
Alopecia - Dormant Projects, H1 2017
Alopecia - Dormant Projects, H1 2017 (Contd..1), H1 2017
Alopecia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Alopecia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *